Norris Medicines Profile
Key Indicators
- Authorised Capital ₹ 10.10 Cr
as on 06-07-2024
- Paid Up Capital ₹ 9.93 Cr
as on 06-07-2024
- Company Age 34 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.57 Cr
as on 06-07-2024
- Satisfied Charges ₹ 7.75 Cr
as on 06-07-2024
- Revenue 55.18%
(FY 2021)
- Profit -74.65%
(FY 2021)
- Ebitda 19.06%
(FY 2021)
- Net Worth -201.02%
(FY 2021)
- Total Assets -3.74%
(FY 2021)
About Norris Medicines
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524414.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.10 Cr and a paid-up capital of Rs 9.93 Cr.
The company currently has active open charges totaling ₹3.57 Cr. The company has closed loans amounting to ₹7.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Norris Medicines Limited India is Iqubal Patel as CFO. Vimal Shah, Shaik Azmathullah, and Mahapatra Susmita serve as directors at the Company.
- CIN/LLPIN
L24230GJ1990PLC086581
- Company No.
086581
- Stock Symbol
BSE : 524414
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Sep 1990
- Date of AGM
14 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Norris Medicines?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Iqubal Patel  | CFO | 31-Mar-2015 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vimal Shah | Director | 20-Feb-2012 | Current |
| Shaik Azmathullah | Director | 06-Aug-2018 | Current |
| Mahapatra Susmita | Director | 16-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of Norris Medicines.
Norris Medicines Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 55.18% increase. The company also saw a substantial fall in profitability, with a 74.65% decrease in profit. The company's net worth observed a substantial decline by a decrease of 201.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Norris Medicines?
In 2022, Norris Medicines had a promoter holding of 34.04% and a public holding of 65.96%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
City Union Bank Limited Creation Date: 27 Jun 2014 | ₹3.57 Cr | Open |
Dena Bank Creation Date: 01 Nov 1995 | ₹7.75 Cr | Satisfied |
How Many Employees Work at Norris Medicines?
Norris Medicines has a workforce of 26 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Norris Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Norris Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
